Apoptosis, proliferation and differentiation patterns are influenced by Zebularine and SAHA in pancreatic cancer models

References

• Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57–70
   PubMed Web of Science ®Google Scholar
• Hruban RH, Goggins M, Parsons J, Kern SE. Progression model for pancreatic cancer. Clin Cancer Res 2000; 6: 2969–72
   PubMed Web of Science ®Google Scholar
• Schneider G, Siveke JT, Eckel F, Schmid RM. Pancreatic cancer: basic and clinical aspects. Gastroenterology 2005; 128: 1606–25
   PubMed Web of Science ®Google Scholar
• Berman DM, Karhadkar SS, Maitra A, Montes De Oca R, Gerstenblith MR, Briggs K, et al. Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours. Nature 2003; 425: 846–51
   PubMed Web of Science ®Google Scholar
• Koizumi M, Doi R, Toyoda E, Masui T, Tulachan SS, Kawaguchi Y, et al. Increased PDX-1 expression is associated with outcome in patients with pancreatic cancer. Surgery 2003; 134: 260–6
   PubMed Web of Science ®Google Scholar
• Song SY, Gannon M, Washington MK, Scoggins CR, Meszoely IM, Goldenring JR, et al. Expansion of Pdx1-expressing pancreatic epithelium and islet neogenesis in transgenic mice overexpressing transforming growth factor alpha. Gastroenterology 1999; 117: 1416–26
   PubMedGoogle Scholar
• Thayer SP, di Magliano MP, Heiser PW, Nielsen CM, Roberts DJ, Lauwers GY, et al. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature 2003; 425: 851–6
   PubMed Web of Science ®Google Scholar
• Neureiter D, Zopf S, Dimmler A, Stintzing S, Hahn EG, Kirchner T, et al. Different capabilities of morphological pattern formation and its association with the expression of differentiation markers in a xenograft model of human pancreatic cancer cell lines. Pancreatology 2005; 5: 387–97
   PubMedGoogle Scholar
• Feinberg AP. The epigenetics of cancer etiology. Semin Cancer Biol 2004; 14: 427–32
   PubMed Web of Science ®Google Scholar
• Lund AH, van Lohuizen M. Epigenetics and cancer. Genes Dev 2004; 18: 2315–35
   PubMed Web of Science ®Google Scholar
• Li E. Chromatin modification and epigenetic reprogramming in mammalian development. Nat Rev Genet 2002; 3: 662–73
   PubMed Web of Science ®Google Scholar
• Fukushima N, Sato N, Ueki T, Rosty C, Walter KM, Wilentz RE, et al. Aberrant methylation of preproenkephalin and p16 genes in pancreatic intraepithelial neoplasia and pancreatic ductal adenocarcinoma. Am J Pathol 2002; 160: 1573–81
   PubMed Web of Science ®Google Scholar
• Ueki T, Toyota M, Sohn T, Yeo CJ, Issa JP, Hruban RH, et al. Hypermethylation of multiple genes in pancreatic adenocarcinoma. Cancer Res 2000; 60: 1835–9
   PubMed Web of Science ®Google Scholar
• Sherr CJ. Principles of tumor suppression. Cell 2004; 116: 235–46
   PubMed Web of Science ®Google Scholar
• Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 1999; 21: 103–7
   PubMed Web of Science ®Google Scholar
• Zhu WG, Otterson GA. The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells. Curr Med Chem Anticancer Agents 2003; 3: 187–99
   PubMedGoogle Scholar
• Brueckner B, Lyko F. DNA methyltransferase inhibitors: old and new drugs for an epigenetic cancer therapy. Trends Pharmacol Sci 2004; 25: 551–4
   PubMed Web of Science ®Google Scholar
• Juttermann R, Li E, Jaenisch R. Toxicity of 5-aza-2′-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. Proc Natl Acad Sci USA 1994; 91: 11797–801
   PubMed Web of Science ®Google Scholar
• Cheng JC, Matsen CB, Gonzales FA, Ye W, Greer S, Marquez VE, et al. Inhibition of DNA methylation and reactivation of silenced genes by zebularine. J Natl Cancer Inst 2003; 95: 399–409
   PubMed Web of Science ®Google Scholar
• Cheng JC, Yoo CB, Weisenberger DJ, Chuang J, Wozniak C, Liang G, et al. Preferential response of cancer cells to zebularine. Cancer Cell 2004; 6: 151–8
   PubMed Web of Science ®Google Scholar
• Sun J, Blaskovich MA, Knowles D, Qian Y, Ohkanda J, Bailey RD, et al. Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: combination therapy with the cytotoxic agents cisplatin, taxol, and gemcitabine. Cancer Res 1999; 59: 4919–26
   PubMed Web of Science ®Google Scholar
• Meadows SL, Gennings C, Carter WH, Jr, Bae DS. Experimental designs for mixtures of chemicals along fixed ratio rays. Environ Health Perspect 2002; 110(Suppl 6)979–83
   PubMedGoogle Scholar
• Tallarida RJ. Drug synergism: its detection and applications. J Pharmacol Exp Ther 2001; 298: 865–72
   PubMed Web of Science ®Google Scholar
• Caldas C, Hahn SA, da Costa LT, Redston MS, Schutte M, Seymour AB, et al. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 1994; 8: 27–32
   PubMed Web of Science ®Google Scholar
• Sipos B, Moser S, Kalthoff H, Torok V, Lohr M, Kloppel G. A comprehensive characterization of pancreatic ductal carcinoma cell lines: towards the establishment of an in vitro research platform. Virchows Arch 2003; 442: 444–52
   PubMed Web of Science ®Google Scholar
• Dote H, Cerna D, Burgan WE, Carter DJ, Cerra MA, Hollingshead MG, et al. Enhancement of in vitro and in vivo tumor cell radiosensitivity by the DNA methylation inhibitor zebularine. Clin Cancer Res 2005; 11: 4571–9
   PubMed Web of Science ®Google Scholar
• Donadelli M, Costanzo C, Faggioli L, Scupoli MT, Moore PS, Bassi C, et al. Trichostatin A, an inhibitor of histone deacetylases, strongly suppresses growth of pancreatic adenocarcinoma cells. Mol Carcinog 2003; 38: 59–69
   PubMedGoogle Scholar
• Mei S, Ho AD, Mahlknecht U. Role of histone deacetylase inhibitors in the treatment of cancer [review]. Int J Oncol 2004; 25: 1509–19
   PubMed Web of Science ®Google Scholar
• Sato N, Ohta T, Kitagawa H, Kayahara M, Ninomiya I, Fushida S, et al. FR901228, a novel histone deacetylase inhibitor, induces cell cycle arrest and subsequent apoptosis in refractory human pancreatic cancer cells. Int J Oncol 2004; 24: 679–85
   PubMed Web of Science ®Google Scholar
• Kelly WK, Richon VM, O'Connor O, Curley T, MacGregor-Curtelli B, Tong W, et al. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 2003; 9: 3578–88
   PubMed Web of Science ®Google Scholar
• Finnin MS, Donigian JR, Cohen A, Richon VM, Rifkind RA, Marks PA, et al. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 1999; 401: 188–93
   PubMed Web of Science ®Google Scholar
• Butler LM, Agus DB, Scher HI, Higgins B, Rose A, Cordon-Cardo C, et al. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res 2000; 60: 5165–70
   PubMed Web of Science ®Google Scholar
• He LZ, Tolentino T, Grayson P, Zhong S, Warrell RP, Jr, Rifkind RA, et al. Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J Clin Invest 2001; 108: 1321–30
   PubMed Web of Science ®Google Scholar
• Driscoll JS, Marquez VE, Plowman J, Liu PS, Kelley JA, Barchi JJ, Jr. Antitumor properties of 2(1H)-pyrimidinone riboside (zebularine) and its fluorinated analogues. J Med Chem 1991; 34: 3280–4
   PubMed Web of Science ®Google Scholar
• Hellebrekers DM, Jair KW, Vire E, Eguchi S, Hoebers NT, Fraga MF, et al. Angiostatic activity of DNA methyltransferase inhibitors. Mol Cancer Ther 2006; 5: 467–75
   PubMed Web of Science ®Google Scholar
• Herranz M, Martin-Caballero J, Fraga MF, Ruiz-Cabello J, Flores JM, Desco M, et al. The novel DNA methylation inhibitor zebularine is effective against the development of murine T-cell lymphoma. Blood 2006; 107: 1174–7
   PubMed Web of Science ®Google Scholar
• Yoo CB, Cheng JC, Jones PA. Zebularine: a new drug for epigenetic therapy. Biochem Soc Trans 2004; 32: 910–2
   PubMedGoogle Scholar
• Holleran JL, Parise RA, Joseph E, Eiseman JL, Covey JM, Glaze ER, et al. Plasma pharmacokinetics, oral bioavailability, and interspecies scaling of the DNA methyltransferase inhibitor, zebularine. Clin Cancer Res 2005; 11: 3862–8
   PubMed Web of Science ®Google Scholar
• Zhou L, Cheng X, Connolly BA, Dickman MJ, Hurd PJ, Hornby DP. Zebularine: a novel DNA methylation inhibitor that forms a covalent complex with DNA methyltransferases. J Mol Biol 2002; 321: 591–9
   PubMed Web of Science ®Google Scholar
• Cecconi D, Astner H, Donadelli M, Palmieri M, Missiaglia E, Hamdan M, et al. Proteomic analysis of pancreatic ductal carcinoma cells treated with 5-aza-2′deoxycytidine. Electrophoresis 2003; 24: 4291–303
   PubMedGoogle Scholar
• Hagihara A, Miyamoto K, Furuta J, Hiraoka N, Wakazono K, Seki S, et al. Identification of 27 5′ CpG islands aberrantly methylated and 13 genes silenced in human pancreatic cancers. Oncogene 2004; 23: 8705–10
   PubMedGoogle Scholar
• Komazaki T, Nagai H, Emi M, Terada Y, Yabe A, Jin E, et al. Hypermethylation-associated inactivation of the SOCS-1 gene, a JAK/STAT inhibitor, in human pancreatic cancers. Jpn J Clin Oncol 2004; 34: 191–4
   PubMed Web of Science ®Google Scholar
• Sato N, Fukushima N, Maitra A, Matsubayashi H, Yeo CJ, Cameron JL, et al. Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays. Cancer Res 2003; 63: 3735–42
   PubMed Web of Science ®Google Scholar
• Ueki T, Toyota M, Skinner H, Walter KM, Yeo CJ, Issa JP, et al. Identification and characterization of differentially methylated CpG islands in pancreatic carcinoma. Cancer Res 2001; 61: 8540–6
   PubMed Web of Science ®Google Scholar
• Sausville EA, Burger AM. Contributions of human tumor xenografts to anticancer drug development. Cancer Res 2006;66:3351–4; discussion 3354.
   PubMed Web of Science ®Google Scholar
• Joo YE, Rew JS, Park CS, Kim SJ. Expression of E-cadherin, alpha- and beta-catenins in patients with pancreatic adenocarcinoma. Pancreatology 2002; 2: 129–37
   PubMedGoogle Scholar
• Qiao Q, Ramadani M, Gansauge S, Gansauge F, Leder G, Beger HG. Reduced membranous and ectopic cytoplasmic expression of beta-catenin correlate with cyclin D1 overexpression and poor prognosis in pancreatic cancer. Int J Cancer 2001; 95: 194–7
   PubMed Web of Science ®Google Scholar
• Miyamoto Y, Maitra A, Ghosh B, Zechner U, Argani P, Iacobuzio-Donahue CA, et al. Notch mediates TGF alpha-induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell 2003; 3: 565–76
   PubMed Web of Science ®Google Scholar
• Nio Y, Omori H, Toga T, Hashimoto K, Itakura M, Koike M, et al. Immunohistochemical expression of receptor-tyrosine kinase c-kit protein in invasive ductal carcinoma of the pancreas. Anticancer Drugs 2003; 14: 313–9
   PubMedGoogle Scholar
• Peters K, Panienka R, Li J, Kloppel G, Wang R. Expression of stem cell markers and transcription factors during the remodeling of the rat pancreas after duct ligation. Virchows Arch 2005; 446: 56–63
   PubMed Web of Science ®Google Scholar
• Kawa S, Nikaido T, Unno H, Usuda N, Nakayama K, Kiyosawa K. Growth inhibition and differentiation of pancreatic cancer cell lines by PPAR gamma ligand troglitazone. Pancreas 2002; 24: 1–7
   PubMed Web of Science ®Google Scholar
• Wetmore C. Sonic hedgehog in normal and neoplastic proliferation: insight gained from human tumors and animal models. Curr Opin Genet Dev 2003; 13: 34–42
   PubMed Web of Science ®Google Scholar